{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:28:02Z","timestamp":1793863682073,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Novel therapies are urgently needed for ovarian cancer, the deadliest gynecologic malignancy. Ovarian cancer has thus far been refractory to immunotherapies that stimulate the host immune system to recognize and kill cancer cells. This may be because of a suppressive tumor immune microenvironment and lack of recruitment and activation of immune cells that kill cancer cells. Our previous work showed that epigenetic drugs including DNA methyltransferase inhibitors and histone deacetylase 6 inhibitors (DNMTis and HDAC6is) individually increase immune signaling in cancer cells. We find that combining DNMTi and HDAC6i results in an amplified type I interferon response, leading to increased cytokine and chemokine expression and higher expression of the MHC I antigen presentation complex in human and mouse ovarian cancer cell lines. Treating mice bearing ID8 Trp53\u2212\/\u2212 ovarian cancer with HDAC6i\/DNMTi led to an increase in tumor-killing cells such as IFNg+ CD8, NK, and NKT cells and a reversal of the immunosuppressive tumor microenvironment with a decrease in MDSCs and PD-1<jats:sup>hi<\/jats:sup> CD4 T cells, corresponding with an increase in survival. Thus combining the epigenetic modulators DNMTi and HDAC6i increases anti-tumor immune signaling from cancer cells and has beneficial effects on the ovarian tumor immune microenvironment.<\/jats:p>","DOI":"10.1038\/s41598-020-60409-4","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:03:14Z","timestamp":1582714994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Sara","family":"Moufarrij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneil","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-6296","authenticated-orcid":false,"given":"Paul Tran","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micael","family":"Lopez-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Villagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Chiappinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"60409_CR1","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668\u2013679 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"60409_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PT Kroeger","year":"2017","unstructured":"Kroeger, P. T. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26\u201334 (2017).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"60409_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15, 564\u2013576 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"60409_CR4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Sci. 331, 1565\u20131570 (2011).","journal-title":"Sci."},{"key":"60409_CR5","doi-asserted-by":"crossref","unstructured":"Durgeau, A., Virk, Y., Corgnac, S. & Mami-Chouaib, F. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol 9 (2018).","DOI":"10.3389\/fimmu.2018.00014"},{"key":"60409_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"60409_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"60409_CR8","doi-asserted-by":"crossref","unstructured":"Baylin, S. B. & Jones, P. A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 8 (2016).","DOI":"10.1101\/cshperspect.a019505"},{"key":"60409_CR9","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas, E. et al. Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes. Clin. Cancer Res. 11, 3604\u20133608 (2005).","journal-title":"Clin. Cancer Res."},{"key":"60409_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974\u2013986 (2015).","journal-title":"Cell"},{"key":"60409_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li, H. et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5, 587 (2014).","journal-title":"Oncotarget"},{"key":"60409_CR12","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone, M. L. et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl. Acad. Sci. USA 114, E10981\u2013E10990 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60409_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper, M. J. et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell 171, 1284\u20131300.e21 (2017).","journal-title":"Cell"},{"key":"60409_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","volume":"76","author":"KB Chiappinelli","year":"2016","unstructured":"Chiappinelli, K. B., Zahnow, C. A., Ahuja, N. & Baylin, S. B. Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res. 76, 1683\u20131689 (2016).","journal-title":"Cancer Res."},{"key":"60409_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"60409_CR16","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.18632\/oncotarget.1542","volume":"4","author":"J Wrangle","year":"2013","unstructured":"Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with Azacytidine. Oncotarget 4, 2067 (2013).","journal-title":"Oncotarget"},{"key":"60409_CR17","doi-asserted-by":"publisher","first-page":"14007","DOI":"10.1073\/pnas.96.24.14007","volume":"96","author":"AR Karpf","year":"1999","unstructured":"Karpf, A. R. et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc. Natl. Acad. Sci. USA 96, 14007\u201314012 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60409_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/mol.65.1.18","volume":"65","author":"AR Karpf","year":"2004","unstructured":"Karpf, A. R. et al. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2\u2019-deoxycytidine. Mol. Pharmacol. 65, 18\u201327 (2004).","journal-title":"Mol. Pharmacol."},{"key":"60409_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/2413","volume":"20","author":"CP Walsh","year":"1998","unstructured":"Walsh, C. P., Chaillet, J. R. & Bestor, T. H. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat. Genet. 20, 116\u2013117 (1998).","journal-title":"Nat. Genet."},{"key":"60409_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/jcb.240360203","volume":"36","author":"M Cohen","year":"1988","unstructured":"Cohen, M., Kato, N. & Larsson, E. ERV3 human endogenous provirus mRNAs are expressed in normal and malignant tissues and cells, but not in choriocarcinoma tumor cells. J. Cell. Biochem. 36, 121\u2013128 (1988).","journal-title":"J. Cell. Biochem."},{"key":"60409_CR21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1093\/nar\/gkp1214","volume":"38","author":"J Gimenez","year":"2010","unstructured":"Gimenez, J. et al. Custom human endogenous retroviruses dedicated microarray identifies self-induced HERV-W family elements reactivated in testicular cancer upon methylation control. Nucleic Acids Res. 38, 2229 (2010).","journal-title":"Nucleic Acids Res."},{"key":"60409_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.4049\/jimmunol.1302972","volume":"192","author":"G Kassiotis","year":"2014","unstructured":"Kassiotis, G. Endogenous retroviruses and the development of cancer. J. immunology 192, 1343 (2014).","journal-title":"J. immunology"},{"key":"60409_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2009.02.008","volume":"280","author":"JM Larsen","year":"2009","unstructured":"Larsen, J. M. et al. Syncytin immunoreactivity in colorectal cancer: Potential prognostic impact. Cancer Lett. 280, 44\u201349 (2009).","journal-title":"Cancer Lett."},{"key":"60409_CR24","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/gcc.20751","volume":"49","author":"S Stengel","year":"2010","unstructured":"Stengel, S., Fiebig, U., Kurth, R. & Denner, J. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes. Chromosom. Cancer 49, 401\u2013411 (2010).","journal-title":"Genes. Chromosom. Cancer"},{"key":"60409_CR25","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.18632\/oncotarget.679","volume":"3","author":"PL Strissel","year":"2012","unstructured":"Strissel, P. L. et al. Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: Emergence of new molecular targets. Oncotarget 3, 1204\u20131219 (2012).","journal-title":"Oncotarget"},{"key":"60409_CR26","first-page":"1553","volume":"7","author":"F Wang-Johanning","year":"2001","unstructured":"Wang-Johanning, F. et al. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin. Cancer Res. 7, 1553\u20131560 (2001).","journal-title":"Clin. Cancer Res."},{"key":"60409_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ijc.22256","volume":"120","author":"F Wang-Johanning","year":"2007","unstructured":"Wang-Johanning, F. et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int. J. Cancer 120, 81\u201390 (2007).","journal-title":"Int. J. Cancer"},{"key":"60409_CR28","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.humpath.2006.10.018","volume":"38","author":"L-I Larsson","year":"2007","unstructured":"Larsson, L.-I., Holck, S. & Christensen, I. J. Prognostic role of syncytin expression in breast cancer. Hum. Pathol. 38, 726\u2013731 (2007).","journal-title":"Hum. Pathol."},{"key":"60409_CR29","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1158\/1078-0432.CCR-14-3197","volume":"21","author":"J Krishnamurthy","year":"2015","unstructured":"Krishnamurthy, J. et al. Genetic Engineering of T cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin. Cancer Res. 21, 3241\u20133251 (2015).","journal-title":"Clin. Cancer Res."},{"key":"60409_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature14308","volume":"522","author":"EJ Grow","year":"2015","unstructured":"Grow, E. J. et al. Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells. Nat. 522, 221\u2013225 (2015).","journal-title":"Nat."},{"key":"60409_CR31","doi-asserted-by":"crossref","unstructured":"Giri, A. K. & Aittokallio, T. DNMT Inhibitors Increase Methylation in the Cancer Genome. Front. Pharmacol. 10 (2019).","DOI":"10.3389\/fphar.2019.00385"},{"key":"60409_CR32","first-page":"166","volume":"3","author":"H-J Kim","year":"2011","unstructured":"Kim, H.-J. & Bae, S.-C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 3, 166\u2013179 (2011).","journal-title":"Am. J. Transl. Res."},{"key":"60409_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug. Discov. 13, 673\u2013691 (2014).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"60409_CR34","doi-asserted-by":"publisher","first-page":"875824","DOI":"10.1155\/2011\/875824","volume":"2011","author":"GI Aldana-Masangkay","year":"2011","unstructured":"Aldana-Masangkay, G. I. & Sakamoto, K. M. The role of HDAC6 in cancer. J. Biomed. Biotechnol. 2011, 875824 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"60409_CR35","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.4049\/jimmunol.1302778","volume":"193","author":"F Cheng","year":"2014","unstructured":"Cheng, F. et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3\/IL-10 pathway in APCs. J. Immunol. 193, 2850\u20132862 (2014).","journal-title":"J. Immunol."},{"key":"60409_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.molimm.2014.02.019","volume":"60","author":"F Cheng","year":"2014","unstructured":"Cheng, F. et al. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol. Immunol. 60, 44\u201353 (2014).","journal-title":"Mol. Immunol."},{"key":"60409_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"T Knox","year":"2019","unstructured":"Knox, T. et al. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci. Rep. 9, 1\u201317 (2019).","journal-title":"Sci. Rep."},{"key":"60409_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1074-7613(04)00078-0","volume":"20","author":"JM Serrador","year":"2004","unstructured":"Serrador, J. M. et al. HDAC6 Deacetylase Activity Links the Tubulin Cytoskeleton with Immune Synapse Organization. Immun. 20, 417\u2013428 (2004).","journal-title":"Immun."},{"key":"60409_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","volume":"10","author":"M Lienlaf","year":"2016","unstructured":"Lienlaf, M. et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol. Oncol. 10, 735\u2013750 (2016).","journal-title":"Mol. Oncol."},{"key":"60409_CR40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.molonc.2015.04.002","volume":"9","author":"KV Woan","year":"2015","unstructured":"Woan, K. V. et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol. Oncol. 9, 1447\u20131457 (2015).","journal-title":"Mol. Oncol."},{"key":"60409_CR41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ncb3582","volume":"19","author":"BG Bitler","year":"2017","unstructured":"Bitler, B. G. et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol. 19, 962\u2013973 (2017).","journal-title":"Nat. Cell Biol."},{"key":"60409_CR42","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.celrep.2018.03.019","volume":"22","author":"T Fukumoto","year":"2018","unstructured":"Fukumoto, T. et al. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep. 22, 3393\u20133400 (2018).","journal-title":"Cell Rep."},{"key":"60409_CR43","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.18632\/oncotarget.1961","volume":"5","author":"F Fang","year":"2014","unstructured":"Fang, F. et al. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 5, 3579\u20133589 (2014).","journal-title":"Oncotarget"},{"key":"60409_CR44","doi-asserted-by":"publisher","unstructured":"Fang, F. et al. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs. Cancer Res., https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1492 (2017).","DOI":"10.1158\/0008-5472.CAN-17-1492"},{"key":"60409_CR45","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","volume":"72","author":"D Matei","year":"2012","unstructured":"Matei, D. et al. Epigenetic Resensitization to Platinum in Ovarian Cancer. Cancer Res. 72, 2197\u20132205 (2012).","journal-title":"Cancer Res."},{"key":"60409_CR46","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton, J. et al. CRISPR\/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. Cancer Res. 76, 6118\u20136129 (2016).","journal-title":"Cancer Res."},{"key":"60409_CR47","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1038\/s41388-018-0238-8","volume":"37","author":"W Zhou","year":"2018","unstructured":"Zhou, W. et al. Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. Oncogene 37, 3981\u20133997 (2018).","journal-title":"Oncogene"},{"key":"60409_CR48","doi-asserted-by":"publisher","first-page":"e0179501","DOI":"10.1371\/journal.pone.0179501","volume":"12","author":"C Siebenk\u00e4s","year":"2017","unstructured":"Siebenk\u00e4s, C. et al. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLOS ONE 12, e0179501 (2017).","journal-title":"PLOS ONE"},{"key":"60409_CR49","doi-asserted-by":"publisher","first-page":"e50256","DOI":"10.7554\/eLife.50256","volume":"8","author":"KW Ng","year":"2019","unstructured":"Ng, K. W. et al. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. elife 8, e50256 (2019).","journal-title":"elife"},{"key":"60409_CR50","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cbin.10729","volume":"41","author":"E Cacan","year":"2017","unstructured":"Cacan, E. Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells. Cell Biol. Int. 41, 328\u2013339 (2017).","journal-title":"Cell Biol. Int."},{"key":"60409_CR51","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.4049\/jimmunol.0802960","volume":"183","author":"CJ Gamper","year":"2009","unstructured":"Gamper, C. J., Agoston, A. T., Nelson, W. G. & Powell, J. D. Identification of DNA methyltransferase 3a as a T cell receptor-induced regulator of Th1 and Th2 differentiation. J. Immunol. 183, 2267\u20132276 (2009).","journal-title":"J. Immunol."},{"key":"60409_CR52","doi-asserted-by":"publisher","first-page":"10631","DOI":"10.1073\/pnas.1524490113","volume":"113","author":"BH Ladle","year":"2016","unstructured":"Ladle, B. H. et al. De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation. Proc. Natl. Acad. Sci. USA 113, 10631\u201310636 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60409_CR53","doi-asserted-by":"publisher","first-page":"22900","DOI":"10.1074\/jbc.M111.312785","volume":"287","author":"RM Thomas","year":"2012","unstructured":"Thomas, R. M., Gamper, C. J., Ladle, B. H., Powell, J. D. & Wells, A. D. De Novo DNA Methylation Is Required to Restrict T Helper Lineage Plasticity. J. Biol. Chem. 287, 22900\u201322909 (2012).","journal-title":"J. Biol. Chem."},{"key":"60409_CR54","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature25144","volume":"552","author":"B Youngblood","year":"2017","unstructured":"Youngblood, B. et al. Effector CD8 T cells dedifferentiate into long-lived memory cells. Nat. 552, 404\u2013409 (2017).","journal-title":"Nat."},{"key":"60409_CR55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim, H. E. et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell 170, 142\u2013157.e19 (2017).","journal-title":"Cell"}],"updated-by":[{"DOI":"10.1038\/s41598-021-04066-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60409-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60409-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60409-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:32:07Z","timestamp":1670311927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60409-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60409"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60409-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-021-04066-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"23 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-04066-1","URL":"https:\/\/doi.org\/10.1038\/s41598-021-04066-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3470"}}